Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mei-Mei Zheng
Observed names:
M. Zheng,
M.-M. Zheng,
M.M. Zheng,
Mei-mei Zheng,
Meimei Zheng,
Mei‐Mei Zheng,
Zheng, Mei-Mei
show all 7
Institutions:
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital,
Southern Medical University
Observed institutions:
National Taiwan University,
Guangdong General Hospital,
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital,
Southern Medical University,
South China University of Technology
show all 6
ORCID:
0000-0002-3493-7139
Observed ORCID:
0000-0002-3493-7139
OpenAlex ID:
A5081175121
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
2018
·
Y.S. Li
, B.Y. Jiang
, et al.
·
Annals of Oncology
·
318
Emerging evidence and treatment paradigm of non-small cell lung cancer
2023
·
Si-Yang Maggie Liu
, Mei-Mei Zheng
, et al.
·
Journal of Hematology & Oncology
·
119
PDF
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC
2019
·
Mei-Mei Zheng
, Yang-Si Li
, et al.
·
Journal of Thoracic Oncology
·
117
Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC
2020
·
Mei-Mei Zheng
, Yang-Si Li
, et al.
·
Journal of Thoracic Oncology
·
82
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
2021
·
Lun-Xi Peng
, Guang-Ling Jie
, et al.
·
Experimental Hematology and Oncology
·
63
PDF
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
2025
·
Li-Bo Tang
, Ying-Long Peng
, et al.
·
Nature Reviews Clinical Oncology
·
57
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases
2025
·
Mei-Mei Zheng
, Qing Zhou
, et al.
·
Nature Medicine
·
37
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC
2024
·
Yang-Si Li
, Wen-Pu Lai
, et al.
·
Cell Reports
·
37
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases
2019
·
Kai Yin
, Yang-Si Li
, et al.
·
Lung Cancer
·
35
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer
2020
·
Sachiko Arai
, Shinji Takeuchi
, et al.
·
Journal of Thoracic Oncology
·
32
PDF
Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments
2021
·
Mei-Mei Zheng
, Hai-Yan Tu
, et al.
·
European Journal of Cancer
·
30
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
2025
·
Yang-Si Li
, Qitao Yu
, et al.
·
Journal of Thoracic Oncology
·
24
PDF
Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases
2020
·
Yang-Si Li
, Mei-Mei Zheng
, et al.
·
JAMA Network Open
·
20
PDF
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
2023
·
Si-Yang Maggie Liu
, Xiao-Rong Dong
, et al.
·
EClinicalMedicine
·
16
PDF
Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
2023
·
Hai‐Yan Tu
, Kai Yin
, et al.
·
Molecular Oncology
·
15
PDF
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
2022
·
Mei-Mei Zheng
, Yang-Si Li
, et al.
·
BMC Medicine
·
15
PDF
Current and future immunotherapies for NSCLC
2026
·
Chu-Yu Zhou
, Yi-Fan Qi
, et al.
·
Journal of Hematology & Oncology
·
9
PDF
Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report
2025
·
Li-Bo Tang
, Ying-Long Peng
, et al.
·
Translational Lung Cancer Research
·
9
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
2023
·
Guang-Ling Jie
, Lun-Xi Peng
, et al.
·
Cancers
·
6
PDF
Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitor–Failed Leptomeningeal Metastases?
2021
·
Mei-Mei Zheng
, Yang-Si Li
, et al.
·
Journal of Thoracic Oncology
·
5
PDF
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases
2025
·
Yang-Si Li
, Wenpu Lai
, et al.
·
Journal for ImmunoTherapy of Cancer
·
4
P1.09-02 Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR mutant NSCLC
2023
·
Y.-S. Li
, K. Yin
, et al.
·
Journal of Thoracic Oncology
·
4
Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
2021
·
Mei-Mei Zheng
, Yang-Si Li
, et al.
·
Journal of Thoracic Oncology
·
4
PDF
LAMPAD: An Integrated Circulating Tumor DNA-Based Model for Predicting Potential Cure in Patients With Resected NSCLC
2026
·
Jia-Tao Zhang
, Ke-Zhong Chen
, et al.
·
Journal of Thoracic Oncology
·
3
“Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC
2024
·
Mei-Mei Zheng
, Yi-Long Wu
·
Journal of Thoracic Oncology
·
2
PDF
Show more works
View as search
Works count:
40
Citation count:
1,067
H-index:
15
I10-index:
16
Year
Topic
Type